ADC Therapeutics (NYSE:ADCT) Shares Down 9.2% - Should You Sell?

Key Points

• Shares of ADC Therapeutics fell about 9.2% to $4.43 on Thursday on thin trading — ~102,116 shares exchanged, roughly an 87% drop vs. average daily volume.
• Analysts are mixed but mildly positive: three Buy vs. one Sell, a consensus rating of "Moderate Buy" and an average price target of $7.33 (range includes Guggenheim's $10 and RBC's $5).
• The company recently beat quarterly expectations with EPS of ($0.04) vs. ($0.32) expected and revenue of $23.06M, but remains loss-making with a full‑year EPS forecast of -1.69 and a market cap around $551M.

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was down 9.2% on Thursday . The stock traded as low as $4.46 and last traded at $4.43. Approximately 102,116 shares were traded during trading, a decline of 87% from the average daily volume of 805,532 shares. The stock had previously closed at $4.88.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ADCT. Weiss Ratings restated a "sell (d-)" rating on shares of ADC Therapeutics in a research report on Wednesday, January 21st. Guggenheim reaffirmed a "buy" rating and issued a $10.00 price objective on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen upgraded ADC Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $5.00 target price on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $7.33.

ADC Therapeutics Trading Down 8.8%

The stock's 50 day moving average is $3.92 and its 200-day moving average is $3.88. The company has a market cap of $551.25 million, a P/E ratio of -3.69 and a beta of 1.92.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.28. The firm had revenue of $23.06 million for the quarter, compared to analysts' expectations of $22.29 million. As a group, sell-side analysts forecast that ADC Therapeutics SA will post -1.69 EPS for the current year.

Institutional Investors Weigh In On ADC Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP purchased a new position in ADC Therapeutics during the fourth quarter valued at $43,000. ProShare Advisors LLC grew its position in shares of ADC Therapeutics by 27.0% during the fourth quarter. ProShare Advisors LLC now owns 15,727 shares of the company's stock valued at $56,000 after purchasing an additional 3,339 shares in the last quarter. AXQ Capital LP bought a new stake in ADC Therapeutics in the 4th quarter worth approximately $57,000. R Squared Ltd purchased a new stake in shares of ADC Therapeutics during the 3rd quarter worth approximately $59,000. Finally, Henrickson Nauta Wealth Advisors Inc. purchased a new stake in shares of ADC Therapeutics during the 4th quarter worth approximately $69,000. Institutional investors own 41.10% of the company's stock.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.